在肝细胞癌中探索JAK/STAT信号通路:解开信号复杂性和治疗影响
Hyunjung Park1, Sangjik Lee1, Jaehun Lee1
1Department of Genetics and Biotechnology, College of Life Sciences, Kyung Hee University, Yongin-si 17104, Republic of Korea.
准简氏激酶 (JAK) 和信号转换器和转录激活器 (STAT) 途径为肝细胞癌 (HCC) 提供了一个有前途的治疗策略. 本综述探讨了JAK/STAT信号的使用情况.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 在癌症中的分子信号通路.
- 瘤发生和癌症免疫学
背景情况:
- 肝细胞癌 (HCC) 在有限的治疗选择下,对全球健康造成重大负担.
- 简氏激酶 (JAK) 和信号转换器和转录激活器 (STAT) 途径越来越被认为是HCC发展的关键参与者.
- 慢性肝炎和肝硬化通常涉及失调的细胞因子和生长因子信号,影响JAK/STAT通路.
研究的目的:
- 在肝细胞癌的背景下,提供JAK/STAT信号通路的全面概述.
- 阐明持续的JAK/STAT激活驱动肝癌发生的机制.
- 审查目前针对JAK/STAT途径的治疗策略,以治疗HCC.
主要方法:
- 对HCC中JAK/STAT途径抑制剂的临床前和临床研究的文献综述.
- 分析上游激活剂与JAK/STAT信号在肝脏病变发生过程中的相互作用.
- 检查由JAK/STAT信号驱动的致癌过程,包括扩散,亡逃避和免疫逃逸.
主要成果:
- 持续的JAK/STAT激活促进了不受控制的细胞增殖,抑制了细胞亡,并促进了HCC的免疫逃避.
- 在临床前和临床环境中,各种JAK/STAT信号的抑制剂和调节剂已经显示出潜在的潜力.
- 针对JAK/STAT路径显示出抑制HCC进展的前景.
结论:
- JAK/STAT信号通路是肝细胞癌的关键调解者.
- 准JAK/STAT信号代表了对HCC的有希望的治疗途径.
- 对JAK/STAT通路调节的持续研究对于开发有效的HCC疗法至关重要.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
The JAK-STAT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
